Advances in geriatric oncology: a multidisciplinary perspective

Ponnandai Somasundar, Loïc Mourey, Laura Lozza, Stefania Maggi, Rob Stepney

Research output: Contribution to journalArticle

Abstract

A growing majority of people with cancer is composed of older patients. For many such patients, independence and quality of life are as important as prolongation of survival, emphasizing the need for treatments that are not only effective but also well-tolerated. Given age-related decline in organ function and the prevalence of comorbidities and polypharmacy, optimum management is complex and requires collaboration between oncologists and geriatricians. Advances in surgery now include preoperative assessment and, when indicated, prehabilitation of the patient, as well as the enhanced recovery after surgery approach. Medical treatment is benefiting from the advent of highly effective novel immunomodulatory agents that join the tumor-targeted small molecule tyrosine kinase inhibitors and monoclonal antibodies in modifying the tolerability of therapy. Improved tolerability is evident with radiotherapy (RT). The adoption of stereotactic body RT in community oncology practice is increasing the proportion of elderly patients with comorbidities who can receive curative treatment. A further aspect of precision medicine as it relates to the older cancer patient is the tailoring of intervention to the robustness or frailty and life expectancy of the individual. Quantitative and validated tools for comprehensive geriatric assessment are playing an important role in this process.

Original languageEnglish
Pages (from-to)252-257
Number of pages6
JournalTumori
Volume104
Issue number4
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Geriatrics
Comorbidity
Geriatric Assessment
Polypharmacy
Neoplasms
Precision Medicine
Radiosurgery
Therapeutics
Life Expectancy
Protein-Tyrosine Kinases
Radiotherapy
Monoclonal Antibodies
Quality of Life
Survival

Keywords

  • Aged
  • Aged, 80 and over
  • Comorbidity
  • Female
  • Geriatric Assessment
  • Geriatrics/trends
  • Humans
  • Life Expectancy
  • Male
  • Medical Oncology/trends
  • Neoplasms/epidemiology
  • Quality of Life
  • Radiosurgery

Cite this

Somasundar, P., Mourey, L., Lozza, L., Maggi, S., & Stepney, R. (2018). Advances in geriatric oncology: a multidisciplinary perspective. Tumori, 104(4), 252-257. https://doi.org/10.5301/tj.5000661

Advances in geriatric oncology : a multidisciplinary perspective. / Somasundar, Ponnandai; Mourey, Loïc; Lozza, Laura; Maggi, Stefania; Stepney, Rob.

In: Tumori, Vol. 104, No. 4, 08.2018, p. 252-257.

Research output: Contribution to journalArticle

Somasundar, P, Mourey, L, Lozza, L, Maggi, S & Stepney, R 2018, 'Advances in geriatric oncology: a multidisciplinary perspective', Tumori, vol. 104, no. 4, pp. 252-257. https://doi.org/10.5301/tj.5000661
Somasundar, Ponnandai ; Mourey, Loïc ; Lozza, Laura ; Maggi, Stefania ; Stepney, Rob. / Advances in geriatric oncology : a multidisciplinary perspective. In: Tumori. 2018 ; Vol. 104, No. 4. pp. 252-257.
@article{0f4fdc4486514675871b5a5b963b7657,
title = "Advances in geriatric oncology: a multidisciplinary perspective",
abstract = "A growing majority of people with cancer is composed of older patients. For many such patients, independence and quality of life are as important as prolongation of survival, emphasizing the need for treatments that are not only effective but also well-tolerated. Given age-related decline in organ function and the prevalence of comorbidities and polypharmacy, optimum management is complex and requires collaboration between oncologists and geriatricians. Advances in surgery now include preoperative assessment and, when indicated, prehabilitation of the patient, as well as the enhanced recovery after surgery approach. Medical treatment is benefiting from the advent of highly effective novel immunomodulatory agents that join the tumor-targeted small molecule tyrosine kinase inhibitors and monoclonal antibodies in modifying the tolerability of therapy. Improved tolerability is evident with radiotherapy (RT). The adoption of stereotactic body RT in community oncology practice is increasing the proportion of elderly patients with comorbidities who can receive curative treatment. A further aspect of precision medicine as it relates to the older cancer patient is the tailoring of intervention to the robustness or frailty and life expectancy of the individual. Quantitative and validated tools for comprehensive geriatric assessment are playing an important role in this process.",
keywords = "Aged, Aged, 80 and over, Comorbidity, Female, Geriatric Assessment, Geriatrics/trends, Humans, Life Expectancy, Male, Medical Oncology/trends, Neoplasms/epidemiology, Quality of Life, Radiosurgery",
author = "Ponnandai Somasundar and Lo{\"i}c Mourey and Laura Lozza and Stefania Maggi and Rob Stepney",
year = "2018",
month = "8",
doi = "10.5301/tj.5000661",
language = "English",
volume = "104",
pages = "252--257",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Advances in geriatric oncology

T2 - a multidisciplinary perspective

AU - Somasundar, Ponnandai

AU - Mourey, Loïc

AU - Lozza, Laura

AU - Maggi, Stefania

AU - Stepney, Rob

PY - 2018/8

Y1 - 2018/8

N2 - A growing majority of people with cancer is composed of older patients. For many such patients, independence and quality of life are as important as prolongation of survival, emphasizing the need for treatments that are not only effective but also well-tolerated. Given age-related decline in organ function and the prevalence of comorbidities and polypharmacy, optimum management is complex and requires collaboration between oncologists and geriatricians. Advances in surgery now include preoperative assessment and, when indicated, prehabilitation of the patient, as well as the enhanced recovery after surgery approach. Medical treatment is benefiting from the advent of highly effective novel immunomodulatory agents that join the tumor-targeted small molecule tyrosine kinase inhibitors and monoclonal antibodies in modifying the tolerability of therapy. Improved tolerability is evident with radiotherapy (RT). The adoption of stereotactic body RT in community oncology practice is increasing the proportion of elderly patients with comorbidities who can receive curative treatment. A further aspect of precision medicine as it relates to the older cancer patient is the tailoring of intervention to the robustness or frailty and life expectancy of the individual. Quantitative and validated tools for comprehensive geriatric assessment are playing an important role in this process.

AB - A growing majority of people with cancer is composed of older patients. For many such patients, independence and quality of life are as important as prolongation of survival, emphasizing the need for treatments that are not only effective but also well-tolerated. Given age-related decline in organ function and the prevalence of comorbidities and polypharmacy, optimum management is complex and requires collaboration between oncologists and geriatricians. Advances in surgery now include preoperative assessment and, when indicated, prehabilitation of the patient, as well as the enhanced recovery after surgery approach. Medical treatment is benefiting from the advent of highly effective novel immunomodulatory agents that join the tumor-targeted small molecule tyrosine kinase inhibitors and monoclonal antibodies in modifying the tolerability of therapy. Improved tolerability is evident with radiotherapy (RT). The adoption of stereotactic body RT in community oncology practice is increasing the proportion of elderly patients with comorbidities who can receive curative treatment. A further aspect of precision medicine as it relates to the older cancer patient is the tailoring of intervention to the robustness or frailty and life expectancy of the individual. Quantitative and validated tools for comprehensive geriatric assessment are playing an important role in this process.

KW - Aged

KW - Aged, 80 and over

KW - Comorbidity

KW - Female

KW - Geriatric Assessment

KW - Geriatrics/trends

KW - Humans

KW - Life Expectancy

KW - Male

KW - Medical Oncology/trends

KW - Neoplasms/epidemiology

KW - Quality of Life

KW - Radiosurgery

U2 - 10.5301/tj.5000661

DO - 10.5301/tj.5000661

M3 - Article

C2 - 28967093

VL - 104

SP - 252

EP - 257

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -